Scientific publications

Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

Mar 16, 2022 | Magazine: European Journal of Vascular and Endovascular Surgery

Goren Saenz-Pipaon  1 , Susana Ravassa  2 , Katrine L Larsen  3 , Esther Martinez-Aguilar  4 , Josune Orbe  5 , Jose A Rodriguez  5 , Leopoldo Fernandez-Alonso  4 , Arantxa Gonzalez  2 , Jose L Martín-Ventura  6 , Jose A Paramo  7 , Jes S Lindholt  3 , Carmen Roncal  8


Objective: Peripheral arterial disease (PAD) is the most prevalent cardiovascular (CV) condition globally. Despite the high CV risk of PAD patients, no reliable predictors of adverse clinical evolution are yet available. In this regard, previous transcriptomic analyses revealed increased expression of calprotectin (S100A8/A9) and lipocalin-2 (LCN2) in circulating extracellular vesicles (EVs) of patients with PAD. The aim of this study was to determine the prognostic value of LCN2 and calprotectin for CV risk assessment in PAD.

Methods: LCN2 and the S100A9 subunit of calprotectin were examined in human femoral plaques by immunohistochemistry and qPCR. LCN2 and calprotectin were determined by ELISA in PAD (CHN cohort, n = 331, Fontaine II-IV, serum), and PAD diagnosed by population based screening (VIVA trial, n = 413, the majority Fontaine 0-I, plasma). Patients were followed up for a mean of four years, recording the primary outcomes; CV death or amputation in the CHN cohort and CV death or major lower limb events (MALE) in the VIVA population. Secondary outcomes were all cause death or amputation, and all cause death or MALE, respectively.

Results: LCN2 and S100A9 were detected in human plaques in regions rich in inflammatory cells. LCN2 and calprotectin levels were 70% and 64% lower in plasma than in serum. In the CHN cohort, high serum levels of LCN2 and calprotectin increased the risk of primary and secondary outcomes 5.6 fold (p < .001) and 1.8 fold (p = .034), respectively, after covariable adjustment. Similarly, elevated plasma levels of LCN2 and calprotectin increased by three fold the risk of primary and secondary outcomes (p < .001) in the VIVA cohort. Moreover, addition of the combined variable to basal models, considering clinically relevant risk factors, improved reclassification for the primary outcome in both cohorts (p ≤ .024).

Conclusion: Combined assessment of the inflammatory biomarkers LCN2 and calprotectin might be useful for risk stratification in advanced and early PAD.

CITATION  Eur J Vasc Endovasc Surg. 2022 Mar 16;S1078-5884(22)00016-8. doi: 10.1016/j.ejvs.2022.01.012